<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0183510</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-13262</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Bacteriophages</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Klebsiella</subject><subj-group><subject>Klebsiella oxytoca</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Klebsiella</subject><subj-group><subject>Klebsiella oxytoca</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Klebsiella</subject><subj-group><subject>Klebsiella oxytoca</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Klebsiella</subject><subj-group><subject>Klebsiella pneumoniae</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Klebsiella</subject><subj-group><subject>Klebsiella pneumoniae</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Klebsiella</subject><subj-group><subject>Klebsiella pneumoniae</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Recombinant proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>DNA-binding proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Computational biology</subject><subj-group><subject>Genome analysis</subject><subj-group><subject>Gene prediction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome analysis</subject><subj-group><subject>Gene prediction</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Gastroenterology and hepatology</subject><subj-group><subject>Diarrhea</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Diarrhea</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Diarrhea</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Characterization and formulation into solid dosage forms of a novel bacteriophage lytic against <italic>Klebsiella oxytoca</italic></article-title>
<alt-title alt-title-type="running-head">Pharmaceutical formulation of novel <italic>K</italic>. <italic>oxytoca</italic> phage</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8885-5668</contrib-id>
<name name-style="western">
<surname>Brown</surname>
<given-names>Teagan L.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Petrovski</surname>
<given-names>Steve</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Hoyle</surname>
<given-names>Dannielle</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Chan</surname>
<given-names>Hiu Tat</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lock</surname>
<given-names>Peter</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Tucci</surname>
<given-names>Joseph</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC, Australia</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Physiology, Anatomy and Microbiology, La Trobe University, Bundoora, VIC, Australia</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Australian Clinical Labs, Clayton, VIC, Australia</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Department of Microbiology, Royal Melbourne Hospital, Parkville, VIC, Australia</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Schuch</surname>
<given-names>Raymond</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Rockefeller University, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>We declare a commercial affiliation: one of the authors (HTC) has a commercial affiliation with Australian Clinical Labs. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">J.Tucci@latrobe.edu.au</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>17</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>12</volume>
<issue>8</issue>
<elocation-id>e0183510</elocation-id>
<history>
<date date-type="received">
<day>5</day>
<month>4</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>4</day>
<month>8</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>Brown et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0183510"/>
<abstract>
<sec id="sec001">
<title>Aim</title>
<p>To isolate and characterize bacteriophage lytic for the opportunistic pathogen <italic>Klebsiella oxytoca</italic> and their formulation into a range of solid dosage forms for <italic>in-vitro</italic> testing.</p>
</sec>
<sec id="sec002">
<title>Methods and results</title>
<p>We report the isolation, genomic and functional characterization of a novel bacteriophage lytic for <italic>Klebsiella oxytoca</italic>, which does not infect the closely related <italic>Klebsiella pneumoniae</italic>. This bacteriophage was formulated into suppositories and troches and shown to be released and lyse underlying <italic>Klebsiella oxytoca</italic> bacteria in an <italic>in-vitro</italic> model. These bacteriophage formulations were stable for at least 49 days at 4°C.</p>
</sec>
<sec id="sec003">
<title>Conclusions</title>
<p>The successful <italic>in-vitro</italic> assay of these formulations here suggests that they could potentially be tested <italic>in-vivo</italic> to determine whether such a therapeutic approach could modulate the gut microbiome, and control <italic>Klebsiella oxytoca</italic> overgrowth, during antibiotic therapy regimes.</p>
</sec>
<sec id="sec004">
<title>Significance and impact of the study</title>
<p>This study reports a novel bacteriophage specific for <italic>Klebsiella oxytoca</italic> which can be formulated into solid dosage forms appropriate for potential delivery in testing as a therapy to modulate gut microbiome during antibiotic therapies.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>One of the authors (HTC) has a commercial affiliation: HTC’s employer (Australian Clinical Labs) provided support in the form of salaries for this author, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors are articulated in the author contributions section.</funding-statement>
</funding-group>
<counts>
<fig-count count="7"/>
<table-count count="2"/>
<page-count count="16"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files. All sequence files are available from the NCBI database (Accession number KY780482).</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>The genus <italic>Klebsiella</italic> represents a group of organisms which despite contributing to the normal flora, are capable of causing serious disease in man. While people may carry these organisms in their gastrointestinal and upper respiratory tract without any symptoms, these bacteria have the capacity to invade and establish infections in these as well as a range of other tissues, including the lower respiratory tract, urinary tract, liver, central nervous system, circulation, cardiac tissue, dental tissue, and wounds [<xref ref-type="bibr" rid="pone.0183510.ref001">1</xref>–<xref ref-type="bibr" rid="pone.0183510.ref006">6</xref>]. The <italic>Klebsiella</italic> species most commonly associated with human disease are <italic>Klebsiella pneumoniae</italic> and <italic>Klebsiella oxytoca</italic> [<xref ref-type="bibr" rid="pone.0183510.ref007">7</xref>]. More recently there have been reports to suggest that <italic>K</italic>. <italic>oxytoca</italic> is the causative agent in a significant proportion (up to 50%) of antibiotic associated haemorrhagic colitis [<xref ref-type="bibr" rid="pone.0183510.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0183510.ref009">9</xref>], and antibiotic associated diarrhoea and may be underdiagnosed because of the lack of sensitivity of the routine laboratory culture media [<xref ref-type="bibr" rid="pone.0183510.ref010">10</xref>]. The <italic>K</italic>. <italic>oxytoca</italic> associated colitis and diarrhoea therefore can significantly decrease the quality of life of the patient and their capacity to tolerated antibiotic regimens [<xref ref-type="bibr" rid="pone.0183510.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0183510.ref009">9</xref>].</p>
<p>A factor that may contribute to the haemorrhagic colitis and diarrhoea caused by <italic>K</italic>. <italic>oxytoca</italic> following antibiotic treatment is that this bacterium is known to carry genes for resistance to an array of antibiotics [<xref ref-type="bibr" rid="pone.0183510.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0183510.ref004">4</xref>]. Its armoury includes chromosomal genes for OXY beta-lactamases and efflux mechanisms such as AcrAb [<xref ref-type="bibr" rid="pone.0183510.ref011">11</xref>] which may confer resistance against later generation cephalosporins [<xref ref-type="bibr" rid="pone.0183510.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0183510.ref012">12</xref>]; and plasmid mediated resistance genes, such as metallo-beta-lactamases, which may enable resistance against carbapenems [<xref ref-type="bibr" rid="pone.0183510.ref013">13</xref>, <xref ref-type="bibr" rid="pone.0183510.ref014">14</xref>]. The environment created under the selective pressure of antibiotic regimes may allow for the specific survival and overgrowth of <italic>K</italic>. <italic>oxytoca</italic>, which is known to constitutively express some of these drug resistance mechanisms [<xref ref-type="bibr" rid="pone.0183510.ref009">9</xref>].</p>
<p>To alleviate symptoms of antibiotic induced colitis and diarrhoea, modulation of intestinal flora represents a potentially useful therapeutic target. While previously demonstrated in animals, very recent studies have shown that faecal microbiota transplantation in humans could minimise the gut colonisation by antibiotic resistant organisms following antibiotic therapy [<xref ref-type="bibr" rid="pone.0183510.ref013">13</xref>, <xref ref-type="bibr" rid="pone.0183510.ref015">15</xref>]. Other less invasive approaches include the use of probiotics, but whilst these have been demonstrated to be efficacious and safe in minimising diarrhoea during antibiotic therapy [<xref ref-type="bibr" rid="pone.0183510.ref016">16</xref>, <xref ref-type="bibr" rid="pone.0183510.ref017">17</xref>], they are not without their adverse reactions [<xref ref-type="bibr" rid="pone.0183510.ref017">17</xref>]. The current use of probiotic modulators of intestinal flora is extensive, with the value of the world market estimated at approximately $35 billion US [<xref ref-type="bibr" rid="pone.0183510.ref018">18</xref>]. As these products are not covered by Pharmaceutical Benefit Schemes, however, the financial cost to the individual patient when using high dosage probiotics is significant.</p>
<p>A possible alternative to the approaches described above for the treatment of antibiotic associated colitis and diarrhoea is the use of lytic bacteriophage (phage), viruses which are endogenous killers of bacterial cells [<xref ref-type="bibr" rid="pone.0183510.ref019">19</xref>, <xref ref-type="bibr" rid="pone.0183510.ref020">20</xref>]. The application of phages to treat bacterial infections is an attractive prospect. Firstly, their action is very specific, as they lyse only their bacterial hosts. Further, they display single-hit kinetics and are auto “dosing” in that their replication at the site of infection leads to marked increases in their titre [<xref ref-type="bibr" rid="pone.0183510.ref021">21</xref>]. Importantly, phages are generally regarded as medically and environmentally safe, bring about minimal disruptions to the autogenous microbial community, and will lyse antibiotic resistant strains [<xref ref-type="bibr" rid="pone.0183510.ref021">21</xref>]. These last two features are particularly relevant in the potential treatment of <italic>K</italic>. <italic>oxytoca</italic>. In 2014, the National Institutes of Health in the U.S. suggested that use of phage was among one of the more innovative and promising components of strategies to combat antimicrobial resistance [<xref ref-type="bibr" rid="pone.0183510.ref022">22</xref>].</p>
<p>To date, a diverse range of applications for phage therapy have been reported, with dosage forms ranging from injections (cutaneous, intravenous, subcutaneous, intrapleural) to liquids [<xref ref-type="bibr" rid="pone.0183510.ref023">23</xref>–<xref ref-type="bibr" rid="pone.0183510.ref025">25</xref>]. We and others have reported the potential of semi-solid preparations for the delivery of phages [<xref ref-type="bibr" rid="pone.0183510.ref026">26</xref>–<xref ref-type="bibr" rid="pone.0183510.ref028">28</xref>]. More recently we tested the efficacy, stability and optimal storage conditions of a range of semi-solid and solid dosage forms for the delivery of lytic phages in an in-vitro model [<xref ref-type="bibr" rid="pone.0183510.ref029">29</xref>]. While several phages that are capable of lysing <italic>K</italic>. <italic>oxytoca</italic> have been reported, these have been propagated on <italic>K</italic>. <italic>pneumoniae</italic> and suggested to have a host range that extends to <italic>K</italic>. <italic>oxytoca</italic> [<xref ref-type="bibr" rid="pone.0183510.ref030">30</xref>, <xref ref-type="bibr" rid="pone.0183510.ref031">31</xref>]. Here we report the isolation, as well as genomic and functional characterization, of novel and unique phage that was propagated on <italic>K</italic>. <italic>oxytoca</italic>, and the subsequent formulation of these into solid dosage forms, namely a troche (or lozenge), and a suppository. These <italic>K</italic>. <italic>oxytoca</italic> phage formulations were then assayed and shown to be capable of releasing the phage so that there was lysis of the underlying <italic>K</italic>. <italic>oxytoca</italic> bacteria in an in-vitro model. The potential benefit of such formulations in the treatment of antibiotic induced <italic>K</italic>. <italic>oxytoca</italic> mediated colitis and diarrhoea is discussed.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Material and methods</title>
<sec id="sec007">
<title>Bacterial cultures and identification</title>
<p><italic>Klebsiella</italic> cultures had been previously isolated from human subjects for other purposes.</p>
<p>All samples were obtained with oral consent, de-identified and handled according to the La Trobe University Ethics committee. No ethical concerns were raised as the human material was not the focus of the study and bacteria obtained were not traced back to the individual.</p>
<p>All cultures were grown using Tryptic Soya broth and agar (Oxoid, Adelaide, Australia). The cultures were incubated at 37°C under anaerobic conditions using the Anaerogen system (Oxoid). Matrix assisted laser desorption ionisation- time of flight (MALDI-TOF) technology was used to initially identify cultures. Isolated single colonies were subjected to biochemical testing and confirmation of identification using the Microbact 24E system (Oxoid), according to the manufacturers’ instructions. For unequivocal identification, PCR amplification of the 16S rRNA gene of each bacterial strain was performed using universal primers 27F, 519R, 895F and 1492R [<xref ref-type="bibr" rid="pone.0183510.ref032">32</xref>–<xref ref-type="bibr" rid="pone.0183510.ref034">34</xref>]. PCR products were cleaned using Ultra Clean® DNA purification kit (MO-BIO, California, USA), and the DNA analysed by Sanger sequencing at the Australian Genome Research Facility (Brisbane, Australia). A feature unique to <italic>K</italic>. <italic>oxytoca</italic> strains, which is not seen in <italic>K</italic>. <italic>pneumoniae</italic>, is the capacity to degrade pectin (via excretion of polygalacturonases), and so as a final differentiation between these species, PCR was performed to test for the presence of the polygalacturonase (pehX) gene [<xref ref-type="bibr" rid="pone.0183510.ref035">35</xref>].</p>
</sec>
<sec id="sec008">
<title>Isolation and purification of phage</title>
<p>A lawn of <italic>K</italic>. <italic>oxytoca</italic> was prepared using a cotton swab, then a 10 μL sample of wastewater (collected from the Bendigo Wastewater Treatment Plant; Bendigo, Australia) was placed directly onto the lawn surface and the plate incubated for 2 days. If clearing was observed, the plaque was excised along with the agar, resuspended in 500 μL of broth and centrifuged (17,000 x <italic>g</italic> for 5 min) as described previously [<xref ref-type="bibr" rid="pone.0183510.ref036">36</xref>]. The supernatant was removed, placed in a fresh tube and a 10-fold serial dilution of the phage performed. Each dilution was spotted directly onto a lawn of the sensitive <italic>K</italic>. <italic>oxytoca</italic> bacteria and plaques were observed. This purification process was repeated five times to ensure that each plaque resulted from a single infecting virion.</p>
<sec id="sec009">
<title>Extraction of phage DNA</title>
<p>As described in detail previously [<xref ref-type="bibr" rid="pone.0183510.ref026">26</xref>], five mL of phage lysate (&gt;10<sup>9</sup> PFU mL<sup>-1</sup>) was treated with MgCl<sub>2</sub> (final concentration 5 mM), DNase I and RNase A (final concentrations of 10 μg mL<sup>-1</sup>) for 30 minutes at room temperature. Phage virions were recovered by polyethylene glycol (PEG) precipitation using PEG 8000 and sodium chloride (final concentrations 10% wt/vol, and 1 M respectively) at 4°C overnight. The precipitate was centrifuged (17,000 × <bold><italic>g</italic></bold> for 15 min) and the pellet resuspended in nuclease free water (Promega, Sydney, Australia). Phage were exposed to Proteinase K (final concentration 50 μg mL<sup>-1</sup>), EDTA (final concentration 20 mM) and sodium dodecyl sulphate (final concentration of 0.5% [vol/vol]) at 55°C for 1 hour. An equal volume of phenol-chloroform-isoamyl alcohol (29:28:1) was added and thoroughly mixed before being centrifuged at 12,000 × <bold><italic>g</italic></bold> for three minutes. The aqueous phase was carefully removed and an equal volume of isopropanol and 1/10 volume sodium acetate (pH 5) was added. The mixture was left at -20°C overnight to allow DNA precipitation. After centrifugation (12,000 × <bold><italic>g</italic></bold> for 10 min) the supernatant was removed, the DNA pellet was washed with 70% ethanol, air dried and resuspended in 30 μl of nuclease free water (Promega, Sydney, Australia).</p>
</sec>
<sec id="sec010">
<title>Phage sequencing and annotation</title>
<p>As described in detail previously [<xref ref-type="bibr" rid="pone.0183510.ref026">26</xref>], extracted phage DNA was prepared for sequencing using a Nextera® XT DNA sample preparation kit as per the manufacturer’s instructions. The DNA libraries were sequenced using a Miseq® V2 reagent kit (300 cycles) on an Illumina MiSeq® as 150 bp paired end reads. Sequenced reads were assembled <italic>de novo</italic> using CLC workbench (Qiagen, Version 8.5.1), and open reading frames predicted using Glimmer (version 3.02). ARAGORN [<xref ref-type="bibr" rid="pone.0183510.ref037">37</xref>] and tRNAscan-SE [<xref ref-type="bibr" rid="pone.0183510.ref038">38</xref>] were used to predict tRNA and tmRNA present in the sequences. The full genomic nucleotide sequence of the <italic>K</italic>. <italic>oxytoca</italic> phage was deposited into GenBank under accession number KY780482.</p>
</sec>
</sec>
<sec id="sec011">
<title>Transmission electron microscopy</title>
<p>Phage particles were allowed to adsorb to 400-mesh formvar and carbon coated copper grids (ProSciTech, Townsville, Australia) for 5 minutes. Excess solution was removed using filter paper before the grids were negatively stained with three 20 sec applications of 2% [wt/vol] uranyl acetate (Sigma, Sydney, Australia) with removal of excess stain on filter paper after each application. Grids were air-dried for 20 minutes before examination under a JEOL JEM-2100 transmission electron microscope (TEM) operated at an accelerating voltage of 200 kV. High resolution digital images were recorded on a Gatan Orius SC200D 1 wide angle camera with Gatan Microscopy Suite and Digital Micrograph (Version 2.32.888.0) imaging software. Viruses were measured using ImageJ software.</p>
</sec>
<sec id="sec012">
<title><italic>K</italic>. <italic>oxytoca</italic> phage host range</title>
<p>To assess whether the phage could lyse other <italic>Klebsiella</italic> strains, a serial dilution series of the phage stock (~10<sup>9</sup> PFU mL<sup>-1</sup>) was completed. 10 μL of each dilution was spotted directly onto a lawn culture of the <italic>Klebsiella</italic> strains which had been identified as described above (<xref ref-type="table" rid="pone.0183510.t001">Table 1</xref>). <italic>Klebsiella oxytoca</italic> (ATCC 13182) and <italic>Klebsiella pneumoniae</italic> (ATCC 13883) obtained from the American Type Culture Collection (Washington DC, USA) were also used in the host range experiments, as were <italic>Pseudomonas aeruginosa</italic> and <italic>Escherichia coli</italic> (which were part of our laboratory culture collection). The observation of plaques on the lawn culture indicated that the phage was able to infect and lyse the host. The PFU (counts per mL) for each strain were also compared to that of the original host to determine the relative efficiency of plating.</p>
<table-wrap id="pone.0183510.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0183510.t001</object-id>
<label>Table 1</label> <caption><title>Identification of the isolated <italic>Klebsiella</italic> species.</title></caption>
<alternatives>
<graphic id="pone.0183510.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Lab code</th>
<th align="left">MALDI-TOF Identification</th>
<th align="left">Microbact Identification<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref></th>
<th align="left">16S sequencing (closest match)<xref ref-type="table-fn" rid="t001fn002"><sup>b</sup></xref></th>
<th align="left">PehX gene</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">KLEB001</td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic></td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic> Code: 47563776</td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic> strain DSM 30104</td>
<td align="left">Negative</td>
</tr>
<tr>
<td align="left">KLEB002</td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic></td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic> Code: 47562766</td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic> strain DSM 30104</td>
<td align="left">Negative</td>
</tr>
<tr>
<td align="left">KLEB003</td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic></td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic> Code: 47763766</td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic> ATCC 13182</td>
<td align="left">Positive</td>
</tr>
<tr>
<td align="left">KLEB004</td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic></td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic> Code: 47763776</td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic> ATCC 13182</td>
<td align="left">Positive</td>
</tr>
<tr>
<td align="left">KLEB005</td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic></td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic> Code: 47761376</td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic> ATCC 13182</td>
<td align="left">Positive</td>
</tr>
<tr>
<td align="left">KLEB006</td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic></td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic> Code: 47563766</td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic> strain DSM 30104</td>
<td align="left">Negative</td>
</tr>
<tr>
<td align="left">KLEB007</td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic></td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic> Code:47563776</td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic> strain DSM 30104</td>
<td align="left">Negative</td>
</tr>
<tr>
<td align="left">KLEB008</td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic></td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic> Code: 47763766</td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic> ATCC 13182</td>
<td align="left">Positive</td>
</tr>
<tr>
<td align="left">KLEB009</td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic></td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic> Code: 47563776</td>
<td align="left"><italic>K</italic>. <italic>pneumoniae</italic> strain DSM 30104</td>
<td align="left">Negative</td>
</tr>
<tr>
<td align="left">KLEB010</td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic></td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic> Code: 47763766</td>
<td align="left"><italic>K</italic>. <italic>oxytoca</italic> ATCC 13182</td>
<td align="left">Positive</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p><sup>a</sup> Microbact database search using the octal code.</p></fn>
<fn id="t001fn002"><p><sup>b</sup>NCBI Blast analysis using the 16S rRNA sequences (Bacteria and Archaea).</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec013">
<title>One step growth curve</title>
<p>As described in detail previously [<xref ref-type="bibr" rid="pone.0183510.ref026">26</xref>], a phage stock of ~10<sup>9</sup> PFU mL<sup>-1</sup> was added to an exponential phase broth culture of <italic>K</italic>. <italic>oxytoca</italic> (propagation host), to a multiplicity of infection (MOI) of 0.1. After a 10 minute adsorption period [<xref ref-type="bibr" rid="pone.0183510.ref031">31</xref>] the cells were washed twice with broth and resuspended in 1 mL of fresh broth. To minimise the amount of non-adsorbed phage this culture was then diluted 1 in 100. 100 μL samples were taken every 10 minutes to calculate viable phage concentrations (PFU mL<sup>-1</sup>) [<xref ref-type="bibr" rid="pone.0183510.ref031">31</xref>, <xref ref-type="bibr" rid="pone.0183510.ref039">39</xref>].</p>
</sec>
<sec id="sec014">
<title><italic>K</italic>. <italic>oxytoca</italic> phage stability in simulated gastric fluid and bile salts solution</title>
<p>To test phage stability in simulated gastric conditions, a phage stock at a concentration of ~10<sup>9</sup> PFU mL<sup>-1</sup> in simulated gastric fluid [<xref ref-type="bibr" rid="pone.0183510.ref040">40</xref>] with 0.32% (wt/vol) pepsin at pH 2.5 was used. 100 μL samples were taken every 15 minutes to calculate viable phage concentrations (PFU mL<sup>-1</sup>). The same experiment was carried out with 0.5% bile salts (OXOID) in intestinal test solution [<xref ref-type="bibr" rid="pone.0183510.ref040">40</xref>] at pH 6.8 to determine the viability of phage when exposed to emulsifying bile salts.</p>
</sec>
<sec id="sec015">
<title><italic>K</italic>. <italic>oxytoca</italic> phage formulation into suppositories</title>
<p>Suppositories were manufactured according to established formularies [<xref ref-type="bibr" rid="pone.0183510.ref041">41</xref>] with a PBS phage stock at a concentration greater than 10<sup>9</sup> PFU mL<sup>-1</sup>. The suppositories were formulated as follows: gelatin powder and purified water were heated at 100°C until dissolved, before glycerol was added according to the formulation. The product was then cooled to 40 degrees Celsius and the phage was added to a final concentration of 4.5x10<sup>8</sup> PFU per gram of formulation. The formulation was deposited into 1.2 mL silicon molds. To test if the phage were capable of lysing their host bacteria, the suppository was sliced along its longitudinal axis to generate two equal halves, and these were then placed flat side down on an agar lawn of <italic>K</italic>. <italic>oxytoca</italic> bacteria. The plates were incubated at 37°C for 2 days and any lysis of the bacteria in the presence of the suppository was indicated by a clear zone.</p>
</sec>
<sec id="sec016">
<title><italic>K</italic>. <italic>oxytoca</italic> phage formulation into troches</title>
<p>Troches were manufactured according to a formula from the Professional Compounding Chemists of Australia. Silca gel (micronized), stevioside powder, acacia powder and citric acid anhydrous powder were triturated and sieved, before being added to melted polyethylene glycol base (PEG base, PCCA). The formulation was mixed until homogenous, cooled and the phage was added to a final concentration of 4.5x10<sup>8</sup> PFU per gram of formulation. The product was poured into troche molds and allowed to set. The troches were then tested by placing the troche flat onto a lawn of <italic>K</italic>. <italic>oxytoca</italic> bacteria. The plates were incubated at 37°C for 2 days and any lysis of the bacteria in the presence of the troche was indicated by a clear zone.</p>
</sec>
<sec id="sec017">
<title>Stability of the <italic>K</italic>. <italic>oxytoca</italic> phage suppositories and troches</title>
<p>Following their formulation, the phage suppositories and troches were stored at 4°C, protected from light. A qualitative assessment of the capacity for phages to kill <italic>K</italic>. <italic>oxytoca</italic> bacteria was conducted at weekly intervals as detailed above. For the pessary, a quantitative assessment was also conducted. The phage pessary was solubilised in preheated PBS (37°C) at a dilution of 1 in 10 and then used to assess the concentration of viable phage (PFU mL<sup>-1</sup>). Such quantitation was not possible with the phage troche, as there was precipitation of material during the solubilisation process.</p>
</sec>
</sec>
<sec id="sec018" sec-type="results">
<title>Results</title>
<sec id="sec019">
<title>Identification of <italic>Klebsiella</italic> strains</title>
<p>Five <italic>K</italic>. <italic>oxytoca</italic> and five <italic>K</italic>. <italic>pneumoniae</italic> strains were identified as detailed in <xref ref-type="table" rid="pone.0183510.t001">Table 1</xref>. Biochemical analysis (Microbact 24E) revealed that all strains could use glucose, mannitol, xylose, citrate, inositol, rhamnose, sucrose, lactose, arabinose, raffinose and salicin as the sole carbon source. All strains were positive for lysine decarboxylase, acetoin production (VP reaction), ONPG and urease hydrolysis. <italic>K</italic>. <italic>oxytoca</italic> strains were indole positive whereas <italic>K</italic>. <italic>pneumoniae</italic> strains were negative. PCR amplification of the pehX gene was observed in only the <italic>K</italic>. <italic>oxytoca</italic> stains (<xref ref-type="table" rid="pone.0183510.t001">Table 1</xref>).</p>
</sec>
<sec id="sec020">
<title>Isolation of the phage and its genome</title>
<p>Following screening with samples from wastewater treatment plants, visible lytic plaques were detected on KLEB010, one of the <italic>K</italic>. <italic>oxytoca</italic> strains identified in this study. These plaques were less than one millimetre in diameter with no visible ‘halo’ or other disturbance to the surrounding bacterial lawn. The plaques were purified and a stock generated by propagating on KLEB010. DNA was extracted and sequenced (with coverage of over 600 times) using the Illumina MiSeq next generation sequencing platform and the reads were assembled <italic>de novo</italic> with CLC Genomics workbench programs. This <italic>K</italic>. <italic>oxytoca</italic> phage, termed KOX1, had a genome of 50,526 base pairs in length (<xref ref-type="fig" rid="pone.0183510.g001">Fig 1</xref>). KOX1 had a circular dsDNA genome with an average GC content of 51.2% which is lower than that of its host <italic>K</italic>. <italic>oxytoca</italic> (~55%). There were 81 open reading frames (ORFs) predicted from the sequence (see <xref ref-type="fig" rid="pone.0183510.g001">Fig 1</xref>). Analysis of the ORFs revealed that only 30% (25 out of 81) of these could be assigned a putative function (see <xref ref-type="table" rid="pone.0183510.t002">Table 2</xref>). For our presentation, ORFs were labelled from the putative terminases and the genes appeared in a modular structure (<xref ref-type="fig" rid="pone.0183510.g001">Fig 1</xref>). All of the ORFs with a putative ascribed function, including terminases, portal proteins, tail structural proteins, lysis proteins, recombinases and DNA manipulation genes showed close homology to previously isolated <italic>Klebsiella</italic> phage (<xref ref-type="table" rid="pone.0183510.t002">Table 2</xref>). There were no tRNA or tmRNA detected in the sequence.</p>
<fig id="pone.0183510.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0183510.g001</object-id>
<label>Fig 1</label>
<caption>
<title>KOX1 genome.</title>
<p>The arrows indicate the ORFs predicted from the sequence and the direction of their translation. The putative function and the ORF number is noted. Red arrows indicate the putative packaging genes, orange arrows are putative structural genes for the capsid and tail morphology, blue arrows are putative DNA manipulation genes and the green arrows indicate putative lysis genes. Grey arrows are ORFs with no ascribed function.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0183510.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0183510.t002</object-id>
<label>Table 2</label> <caption><title>Summary of KOX1 ORFs with predicted protein function.</title></caption>
<alternatives>
<graphic id="pone.0183510.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">ORF</th>
<th align="left">Polypeptide length</th>
<th align="left">Predicted function <break/>(conserved motif)<xref ref-type="table-fn" rid="t002fn001"><sup>a</sup></xref></th>
<th align="left">Closest match<xref ref-type="table-fn" rid="t002fn002"><sup>b</sup></xref></th>
<th align="left">E-value<xref ref-type="table-fn" rid="t002fn003"><sup>c</sup></xref></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">1</td>
<td align="left">175</td>
<td align="left">Putative terminase small subunit (pfam16677)</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">3e-126</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">535</td>
<td align="left">Putative terminase large subunit (pfam03237)</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">3</td>
<td align="left">440</td>
<td align="left">Putative portal protein</td>
<td align="left">Klebsiella phage vB_KpnS_KpV522</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">4</td>
<td align="left">257</td>
<td align="left">Putative head morphogenesis protein (pfam04233)</td>
<td align="left">Klebsiella phage vB_KpnS_KpV522</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">5</td>
<td align="left">377</td>
<td align="left">Putative major capsid protein</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">13</td>
<td align="left">218</td>
<td align="left">Putative major tail protein (pfam08813)</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">2e-155</td>
</tr>
<tr>
<td align="left">14</td>
<td align="left">109</td>
<td align="left">Putative tail assembly chaperone (pfam08748)</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">3e-76</td>
</tr>
<tr>
<td align="left">15</td>
<td align="left">214</td>
<td align="left">Putative tape measure chaperone<break/>(pfam08748)</td>
<td align="left">Klebsiella phage KLPN1</td>
<td align="left">4e-125</td>
</tr>
<tr>
<td align="left">16</td>
<td align="left">993</td>
<td align="left">Putative tape measure protein (pfam06791 and pfam09718)</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">17</td>
<td align="left">115</td>
<td align="left">Putative minor tail protein (pfam05939)</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">5e-78</td>
</tr>
<tr>
<td align="left">18</td>
<td align="left">251</td>
<td align="left">Putative minor tail protein (pfam05100)</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">19</td>
<td align="left">246</td>
<td align="left">Putative tail assembly protein</td>
<td align="left">Klebsiella phage vB_KpnS_KpV522</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">20</td>
<td align="left">201</td>
<td align="left">Putative tail assembly protein (pfam06805)</td>
<td align="left">Klebsiella phage KLPN1</td>
<td align="left">3e-141</td>
</tr>
<tr>
<td align="left">21</td>
<td align="left">1257</td>
<td align="left">Putative tail fibre protein</td>
<td align="left">Klebsiella phage KLPN1</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">24</td>
<td align="left">154</td>
<td align="left">Putative ssDNA binding protein</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">7e-96</td>
</tr>
<tr>
<td align="left">25</td>
<td align="left">219</td>
<td align="left">Putative recombination protein (pfam04404)</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">2e-161</td>
</tr>
<tr>
<td align="left">26</td>
<td align="left">349</td>
<td align="left">Putative exonuclase (pfam12684)</td>
<td align="left">Klebsiella phage vB_KpnS_KpV522</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">27</td>
<td align="left">321</td>
<td align="left">Putative DNA primase (pfam08273)</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">28</td>
<td align="left">134</td>
<td align="left">Putative transcriptional regulator (pfam14549)</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">1e-93</td>
</tr>
<tr>
<td align="left">29</td>
<td align="left">679</td>
<td align="left">Putative DNA helicase (pfam00271)</td>
<td align="left">Klebsiella phage vB_KpnS_KpV522</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">32</td>
<td align="left">244</td>
<td align="left">Putative DNA adenine methyltransferase (pfam05869)</td>
<td align="left">Klebsiella phage PKP126</td>
<td align="left">4e-178</td>
</tr>
<tr>
<td align="left">38</td>
<td align="left">72</td>
<td align="left">Putative holin</td>
<td align="left">Klebsiella phage vB_KpnS_KpV522</td>
<td align="left">3e-41</td>
</tr>
<tr>
<td align="left">39</td>
<td align="left">161</td>
<td align="left">Putative endolysin (pfam00959)</td>
<td align="left">Klebsiella phage vB_KpnS_KpV522</td>
<td align="left">2e-115</td>
</tr>
<tr>
<td align="left">40</td>
<td align="left">142</td>
<td align="left">Putative spanin</td>
<td align="left">Klebsiella phage vB_KpnS_KpV522</td>
<td align="left">2e-110</td>
</tr>
<tr>
<td align="left">46</td>
<td align="left">231</td>
<td align="left">Putative DNA methylase</td>
<td align="left">Klebsiella phage vB_KpnS_KpV522</td>
<td align="left">6e-170</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p><italic>a</italic> Predicted function is based on amino acid identity, conserved motifs, N-terminal sequencing, and gene location within functional modules.</p></fn>
<fn id="t002fn002"><p><italic>b</italic> The most closely related gene and the name of the organism.</p></fn>
<fn id="t002fn003"><p><italic>c</italic> The probability of obtaining a match by chance as determined by BLAST analysis. Only values of less than 10<sup>−4</sup> were considered significant</p></fn>
<fn id="t002fn004"><p>Note: The ORFs not listed in this table code for proteins with unknown function as determined by BLAST analysis.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec021">
<title>KOX1 characterization</title>
<p>Transmission electron microscopy of KOX1 revealed it belonged to the <italic>Myoviridae</italic> family with a prolate icosahedral head (110 ±2 nm by 80 ±2 nm) and contractile tail (115 ±2 nm) placing the phage in the order <italic>Caudovirales</italic> (<xref ref-type="fig" rid="pone.0183510.g002">Fig 2</xref>). KOX1 was found to be lytic only on <italic>K</italic>. <italic>oxytoca</italic> strains and didn’t lyse <italic>K</italic>. <italic>pneumoniae</italic>, <italic>Escherichia coli</italic> or <italic>Pseudomonas aeruginosa</italic> strains. The phage was able to lyse five of the six <italic>K</italic>. <italic>oxytoca</italic> strains isolated in this study, these being KLEB003, KLEB004, KLEB008 and KLEB010, as well as the ATCC obtained <italic>K</italic>. <italic>oxytoca</italic>. The plaquing efficiency on KLEB008 and ATCC 13182 <italic>K</italic>. <italic>oxytoca</italic> was equal to that of the original host (KLEB010; ~10<sup>8</sup> PFU mL<sup>-1</sup>), whereas on KLEB003 and KLEB004 the plaquing efficiency was an order of magnitude less (~10<sup>7</sup> PFU mL<sup>-1</sup>). While inhibition of growth on the <italic>K</italic>. <italic>pneumoniae</italic> strains (ATCC 13883 and KLEB001) was observed at high phage titres, plaques failed to be produced. One step growth experiments showed that KOX1 had a latent period of 20 minutes and the population burst was 3.0x10<sup>8</sup> PFU mL<sup>-1</sup>, which equated to a burst size of 35 PFU per infected bacteria (<xref ref-type="fig" rid="pone.0183510.g003">Fig 3</xref>; <xref ref-type="supplementary-material" rid="pone.0183510.s001">S1 Table</xref>). Our observations of the latent period concur with those previously demonstrated on <italic>K</italic>. <italic>oxytoca</italic> [<xref ref-type="bibr" rid="pone.0183510.ref030">30</xref>, <xref ref-type="bibr" rid="pone.0183510.ref031">31</xref>]. However, the previously reported burst sizes (measured in PFU per infected cell) were lower than what we estimate here [<xref ref-type="bibr" rid="pone.0183510.ref030">30</xref>].</p>
<fig id="pone.0183510.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0183510.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Transmission electron microscopy of KOX1.</title>
<p>The image on the right shows the phage tail contracted. The scale bars represent 100 nm.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0183510.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0183510.g003</object-id>
<label>Fig 3</label>
<caption>
<title>One step growth curve for KOX1.</title>
<p>Depicted is the population burst size and the latent period (See <xref ref-type="supplementary-material" rid="pone.0183510.s001">S1 Table</xref> for values).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec022">
<title>Phage stability in simulated gastric fluid and bile salts solution</title>
<p>As depicted in <xref ref-type="fig" rid="pone.0183510.g004">Fig 4</xref>, even after 90 minutes exposure, phage viability was minimally affected by bile salts. Upon immediate exposure to simulated gastric fluid (pH 2.5), phage viability was reduced by two orders of magnitude. Under these conditions, there was a steady decrease in phage numbers, until after 90 minutes exposure, viable phage numbers had dropped to under 10<sup>4</sup> PFU mL<sup>-1</sup> (<xref ref-type="fig" rid="pone.0183510.g004">Fig 4</xref>; <xref ref-type="supplementary-material" rid="pone.0183510.s002">S2 Table</xref>).</p>
<fig id="pone.0183510.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0183510.g004</object-id>
<label>Fig 4</label>
<caption>
<title>KOX1 stability in simulated gastric fluid and bile salts solution.</title>
<p>The stability over time for each is indicated by the broken and solid lines respectively. The y-axis is in log scale, with data points representing the mean of three samples. Because the measurements for each of the triplicates were very similar, it was not possible to adequately represent the error bars for standard deviation in the figure (see <xref ref-type="supplementary-material" rid="pone.0183510.s002">S2 Table</xref> for values).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.g004" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec023">
<title>KOX1 formulation into solid dosage forms and capacity to lyse <italic>K</italic>. <italic>oxytoca in vitro</italic></title>
<p>KOX1 phage were formulated into suppositories and troches, which were placed upon lawns of <italic>K</italic>. <italic>oxytoca</italic> bacteria on culture plates. Both formulations were capable of releasing the phage to lyse the underlying bacteria (<xref ref-type="fig" rid="pone.0183510.g005">Fig 5</xref> and <xref ref-type="fig" rid="pone.0183510.g006">Fig 6</xref>). These formulations were tested weekly, and when stored at 4°C the phage suppositories maintained lytic activity for at least 49 days (<xref ref-type="fig" rid="pone.0183510.g007">Fig 7</xref>) and the phage troche maintained lytic activity for 56 days (as visualised by clearing in-vitro). <xref ref-type="fig" rid="pone.0183510.g007">Fig 7</xref> shows that 49 days after formulation, suppositories contained viable phage at a concentration of greater than 10<sup>7</sup> PFU mL<sup>-1</sup> (<xref ref-type="supplementary-material" rid="pone.0183510.s003">S3 Table</xref>).</p>
<fig id="pone.0183510.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0183510.g005</object-id>
<label>Fig 5</label>
<caption>
<title>KOX1 phage lytic activity in a suppository.</title>
<p>The left side of the plate (A) shows effect on growth when a control suppository, with no phage formulated is placed on the bacterial lawn. The right side of the plate (B) shows effect on bacterial growth when a suppository formulated with phage at a final concentration of 4.5x10<sup>8</sup> PFU per gram of formulation is placed on the lawn. While there was some effect seen in (A), most likely due to bacterial disturbance when placing the suppository, the phage lytic activity is clearly observed in B.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.g005" xlink:type="simple"/>
</fig>
<fig id="pone.0183510.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0183510.g006</object-id>
<label>Fig 6</label>
<caption>
<title>KOX1 phage lytic activity in a troche.</title>
<p>The left side of the plate (A) shows effect on growth when a control troche, with no phage formulated is placed on the bacterial lawn. The right side of the plate (B) shows effect on bacterial growth when a troche formulated with phage at a final concentration of 4.5x10<sup>8</sup> PFU per gram of formulation is placed on the lawn. While there was some effect seen in (A), most likely due to bacterial disturbance when placing the troche, the phage lytic activity is clearly observed in B.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.g006" xlink:type="simple"/>
</fig>
<fig id="pone.0183510.g007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0183510.g007</object-id>
<label>Fig 7</label>
<caption>
<title>Quantitation of KOX1 phage suppository lytic activity (see <xref ref-type="supplementary-material" rid="pone.0183510.s003">S3 Table</xref> for values).</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.g007" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec024" sec-type="conclusions">
<title>Discussion</title>
<p>This study aimed to isolate and characterize phage which were lytic against <italic>Klebsiella oxytoca</italic>, and formulate them into dosage forms which could potentially be tested in the control of the gut microbiome during antibiotic therapy. While differentiation between the <italic>Klebsiella</italic> species <italic>pneumoniae</italic> and <italic>oxytoca</italic> is not always straightforward [<xref ref-type="bibr" rid="pone.0183510.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0183510.ref042">42</xref>], in the current study we employed data from the complete sequence of the 16S gene, Microbact® biochemical testing, MALDI-TOF analysis and PCR amplification of the pehX gene from isolated strains in order to obtain a definitive identification. The phage which have been reported to target <italic>Klebsiella</italic> to date show a diverse range of morphology including <italic>Podoviradae</italic> (51% of isolates), <italic>Myoviridae</italic> (33% of isolates) and <italic>Siphoviridae</italic> (16% of isolates) (NCBI nucleotide database, <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nucleotide/" xlink:type="simple">https://www.ncbi.nlm.nih.gov/nucleotide/</ext-link>). Of those which are reported as targeting <italic>K</italic>. <italic>oxytoca</italic>, most belong to the Myoviridae family, with genomes ranging in size from 168 to 174 Kb [<xref ref-type="bibr" rid="pone.0183510.ref030">30</xref>, <xref ref-type="bibr" rid="pone.0183510.ref031">31</xref>, <xref ref-type="bibr" rid="pone.0183510.ref043">43</xref>]. KOX1, the unique <italic>K</italic>. <italic>oxytoca</italic> lytic phage isolated here, belongs to the <italic>Myoviridae</italic> family, but has a much smaller genome of approximately 50.5 Kb. The uniqueness of this phage is underlined by the fact that less than 30% of its ORFs have similarity to genes with any known functionality.</p>
<p>While it has been reported that phage isolated on and lytic against <italic>K</italic>. <italic>pneumoniae</italic> were able to lyse strains of <italic>K</italic>. <italic>oxytoca</italic> [<xref ref-type="bibr" rid="pone.0183510.ref030">30</xref>, <xref ref-type="bibr" rid="pone.0183510.ref031">31</xref>, <xref ref-type="bibr" rid="pone.0183510.ref043">43</xref>], KOX1 was specific for <italic>K</italic>. <italic>oxytoca</italic> bacteria, and did not readily lyse the <italic>K</italic>. <italic>pneumoniae</italic> strains tested here. Yet KOX1 was not without some activity against the <italic>K</italic>. <italic>pneumoniae</italic> strains ATCC 13883 and KLEB001. Here, while there was some bacterial lysis at high phage titres, plaques failed to be produced. <italic>K</italic>. <italic>pneumoniae</italic> strains which are closely related to those isolated and used here, (such as that depicted by Accession number CP014294) do not appear to contain the conserved BREX gene cassette, nor elements of the Argonaute pathway [<xref ref-type="bibr" rid="pone.0183510.ref044">44</xref>], both of which confer resistance to a range of phage. One possibility is that the KOX1 phage bound to the <italic>K</italic>. <italic>pneumoniae</italic> strain and initiated lysis, but then the phenomenon of abortive infection subsequently restricted the production of phage progeny to the extent that plaques were not observed. Additionally, there is some evidence of CRISPR/Cas adaptive immunity systems present in some <italic>K</italic>. <italic>pneumoniae</italic> strains which potentially limit phage infection [<xref ref-type="bibr" rid="pone.0183510.ref045">45</xref>].</p>
<p>We have shown here that the KOX1 phage was able to be formulated into solid dosage forms such as troches and suppositories, and that these formulations were stably maintained for a period of up to 49 and 56 days, respectively, at 4°C. These phage formulations displayed <italic>in-vitro</italic> lytic capacity against <italic>K</italic>. <italic>oxytoca</italic> for up to this period. Quantitative analysis of the phage suppository showed that greater than 10<sup>7</sup> viable phage could be isolated following 49 days storage. Such formulations could potentially be tested for use in the treatment of antibiotic associated haemorrhagic colitis and diarrhoea caused by <italic>K</italic>. <italic>oxytoca</italic>. While these gut pathologies are reversible and symptoms subside following cessation of antibiotic therapy [<xref ref-type="bibr" rid="pone.0183510.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0183510.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0183510.ref012">12</xref>], there is significant impact on the patient quality of life during this period [<xref ref-type="bibr" rid="pone.0183510.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0183510.ref012">12</xref>], and this is potentially exacerbated with antibiotic regimes that continue for extended periods of time. Further, the cost to the patient of products to modulate the intestinal flora during antibiotic therapy, such as probiotics, is significant, while procedures such as faecal microbiota transplantation are invasive and as yet in their infancy. The ingestion of troches or administration of suppositories with <italic>K</italic>. <italic>oxytoca</italic> lytic phages as the medicament could prove a useful way to modulate intestinal flora, and assist in reducing overgrowth of antibiotic resistant <italic>K</italic>. <italic>oxytoca</italic> strains, during antibiotic therapy. To this end, we have shown that the KOX1 phage is capable of surviving in environments simulating the gastric chamber. Specifically, our experiments showed that following 30 minutes exposure to these conditions, in which time the phage may be expected to have passed through the stomach if ingested via a troche, there are still significant numbers (10<sup>5–</sup>10<sup>6</sup> PFU mL<sup>-1</sup>) of viable phage. As low gastric pH is a significant contributor to the reduction in phage numbers, the co-administration of proton pump inhibitor therapy, such as omeprazole, may be used in order to enhance phage viability. Such medication is commonly used for gastric reflux, and has the capacity to decrease stomach acidity to pH 6 [<xref ref-type="bibr" rid="pone.0183510.ref046">46</xref>]. This approach may negate the need for microencapsulation of phage into microspheres, which has been suggested as a means of formulating phage to improve viability following traffic through the gastric chamber [<xref ref-type="bibr" rid="pone.0183510.ref047">47</xref>]. Once viable phage have passaged through the stomach, they will encounter bile salts in the duodenum, but as we have shown here, they are not likely to be adversely affected by such emulsifying agents. If the oral route of delivery for the <italic>K</italic>. <italic>oxytoca</italic> phage, via troches, proves difficult, then administering the phage in a suppository, as we have formulated here, may be preferable.</p>
</sec>
<sec id="sec025" sec-type="conclusions">
<title>Conclusion</title>
<p>We report here the isolation and characterization of a unique lytic phage for <italic>K</italic>. <italic>oxytoca</italic>, which is capable of being stably formulated into solid dosage forms. The <italic>in-vitro</italic> lytic capacity of these formulations against <italic>K</italic>. <italic>oxytoca</italic> bacteria is maintained for at least 49 days, when stored at 4°C. This study may provide the basis for clinical testing of these <italic>K</italic>. <italic>oxytoca</italic> phage formulations in order to modulate the intestinal microbiota during antibiotic therapy, and thus reduce the GI effects associated with <italic>K</italic>. <italic>oxytoca</italic> overgrowth.</p>
</sec>
<sec id="sec026">
<title>Supporting information</title>
<supplementary-material id="pone.0183510.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.s001" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>The values shown in S1 Table were used to generate <xref ref-type="fig" rid="pone.0183510.g003">Fig 3</xref>.</title>
<p>This experiment was completed on three additional occasions with similar results.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0183510.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.s002" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Because the measurements for each of the triplicates in <xref ref-type="fig" rid="pone.0183510.g004">Fig 4</xref> were very similar, it was not possible to adequately represent the error bars for standard deviation.</title>
<p>The values shown in S2 Table were calculated and used to generate <xref ref-type="fig" rid="pone.0183510.g004">Fig 4</xref>.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0183510.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0183510.s003" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>These values were used to generate <xref ref-type="fig" rid="pone.0183510.g007">Fig 7</xref>.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We wish to acknowledge the LIMS Bioimaging Facility for use of the Electron Microscope.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0183510.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Podschun</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ullmann</surname> <given-names>U</given-names></name>. <article-title><italic>Klebsiella</italic> spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors</article-title>. <source>Clin Microbiol Rev</source>. <year>1998</year>;<volume>11</volume>(<issue>4</issue>):<fpage>589</fpage>–<lpage>603</lpage>. Epub 1998/10/10. <object-id pub-id-type="pmid">9767057</object-id>; PubMed Central PMCID: PMCPMC88898.</mixed-citation></ref>
<ref id="pone.0183510.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Biehle</surname> <given-names>LR</given-names></name>, <name name-style="western"><surname>Cottreau</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Filipek</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>O'Donnell</surname> <given-names>JN</given-names></name>, <name name-style="western"><surname>Lasco</surname> <given-names>TM</given-names></name>, <etal>et al</etal>. <article-title>Outcomes and risk factors for mortality among patients treated with Carbapenems for Klebsiella spp. bacteremia</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>11</issue>):<fpage>e0143845</fpage>. Epub 2015/12/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0143845" xlink:type="simple">10.1371/journal.pone.0143845</ext-link></comment> <object-id pub-id-type="pmid">26618357</object-id>; PubMed Central PMCID: PMCPMC4664260.</mixed-citation></ref>
<ref id="pone.0183510.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fujita</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kimura</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yokoyama</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Jin</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Wachino</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Yamada</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Characterization of Piperacillin/Tazobactam-resistant <italic>Klebsiella oxytoca</italic> recovered from a nosocomial outbreak</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>11</issue>):<fpage>e0142366</fpage>. Epub 2015/11/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0142366" xlink:type="simple">10.1371/journal.pone.0142366</ext-link></comment> <object-id pub-id-type="pmid">26539828</object-id>; PubMed Central PMCID: PMCPMC4634934.</mixed-citation></ref>
<ref id="pone.0183510.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oriel</surname> <given-names>BS</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Wong</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Itani</surname> <given-names>KM</given-names></name>. <article-title>Effect of hand antisepsis agent selection and population characteristics on surgical site infection pathogens</article-title>. <source>Surgical infections</source>. <year>2016</year>. Epub 2016/09/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/sur.2016.125" xlink:type="simple">10.1089/sur.2016.125</ext-link></comment> <object-id pub-id-type="pmid">27661850</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Henriques</surname> <given-names>LC</given-names></name>, <name name-style="western"><surname>de Brito</surname> <given-names>LC</given-names></name>, <name name-style="western"><surname>Tavares</surname> <given-names>WL</given-names></name>, <name name-style="western"><surname>Teles</surname> <given-names>RP</given-names></name>, <name name-style="western"><surname>Vieira</surname> <given-names>LQ</given-names></name>, <name name-style="western"><surname>Teles</surname> <given-names>FR</given-names></name>, <etal>et al</etal>. <article-title>Microbial ecosystem analysis in root canal infections refractory to endodontic treatment</article-title>. <source>Journal of endodontics</source>. <year>2016</year>;<volume>42</volume>(<issue>8</issue>):<fpage>1239</fpage>–<lpage>45</lpage>. Epub 2016/07/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.joen.2016.05.014" xlink:type="simple">10.1016/j.joen.2016.05.014</ext-link></comment> <object-id pub-id-type="pmid">27377440</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ullah</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Elbita</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Abdelghany</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Tahir</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Tuli</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Alkilani</surname> <given-names>WZ</given-names></name>, <etal>et al</etal>. <article-title><italic>Klebsiella oxytoca</italic> Endocarditis with complete heart block</article-title>. <source>Journal of investigative medicine high impact case reports</source>. <year>2016</year>;<volume>4</volume>(<issue>3</issue>):2324709616663232. Epub 2016/09/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/2324709616663232" xlink:type="simple">10.1177/2324709616663232</ext-link></comment> <object-id pub-id-type="pmid">27635410</object-id>; PubMed Central PMCID: PMCPMC5011305.</mixed-citation></ref>
<ref id="pone.0183510.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Asensio</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Oliver</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gonzalez-Diego</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Baquero</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Perez-Diaz</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Ros</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Outbreak of a multiresistant <italic>Klebsiella pneumoniae</italic> strain in an intensive care unit: antibiotic use as risk factor for colonization and infection</article-title>. <source>Clinical infectious diseases: an official publication of the Infectious Diseases Society of America</source>. <year>2000</year>;<volume>30</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>60</lpage>. Epub 2000/01/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/313590" xlink:type="simple">10.1086/313590</ext-link></comment> <object-id pub-id-type="pmid">10619733</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hogenauer</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Langner</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Beubler</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Lippe</surname> <given-names>IT</given-names></name>, <name name-style="western"><surname>Schicho</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Gorkiewicz</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title><italic>Klebsiella oxytoca</italic> as a causative organism of antibiotic-associated hemorrhagic colitis</article-title>. <source>The New England journal of medicine</source>. <year>2006</year>;<volume>355</volume>(<issue>23</issue>):<fpage>2418</fpage>–<lpage>26</lpage>. Epub 2006/12/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa054765" xlink:type="simple">10.1056/NEJMoa054765</ext-link></comment> <object-id pub-id-type="pmid">17151365</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yilmaz</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bilir</surname> <given-names>YA</given-names></name>, <name name-style="western"><surname>Aygun</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Erzin</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ozturk</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Celik</surname> <given-names>AF</given-names></name>. <article-title>Prospective observational study on antibiotic-associated bloody diarrhea: report of 21 cases with a long-term follow-up from Turkey</article-title>. <source>European journal of gastroenterology &amp; hepatology</source>. <year>2012</year>;<volume>24</volume>(<issue>6</issue>):<fpage>688</fpage>–<lpage>94</lpage>. Epub 2012/03/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MEG.0b013e328352721a" xlink:type="simple">10.1097/MEG.0b013e328352721a</ext-link></comment> <object-id pub-id-type="pmid">22433794</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cheng</surname> <given-names>VC</given-names></name>, <name name-style="western"><surname>Yam</surname> <given-names>WC</given-names></name>, <name name-style="western"><surname>Tsang</surname> <given-names>LL</given-names></name>, <name name-style="western"><surname>Yau</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Siu</surname> <given-names>GK</given-names></name>, <name name-style="western"><surname>Wong</surname> <given-names>SC</given-names></name>, <etal>et al</etal>. <article-title>Epidemiology of <italic>Klebsiella oxytoca</italic>-associated diarrhea detected by Simmons citrate agar supplemented with inositol, tryptophan, and bile salts</article-title>. <source>J Clin Microbiol</source>. <year>2012</year>;<volume>50</volume>(<issue>5</issue>):<fpage>1571</fpage>–<lpage>9</lpage>. Epub 2012/02/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JCM.00163-12" xlink:type="simple">10.1128/JCM.00163-12</ext-link></comment> <object-id pub-id-type="pmid">22357507</object-id>; PubMed Central PMCID: PMCPMC3347154.</mixed-citation></ref>
<ref id="pone.0183510.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mazzariol</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Zuliani</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Cornaglia</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Rossolini</surname> <given-names>GM</given-names></name>, <name name-style="western"><surname>Fontana</surname> <given-names>R</given-names></name>. <article-title>AcrAB Efflux System: expression and contribution to fluoroquinolone resistance in <italic>Klebsiella</italic> spp</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2002</year>;<volume>46</volume>(<issue>12</issue>):<fpage>3984</fpage>–<lpage>6</lpage>. Epub 2002/11/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.46.12.3984-3986.2002" xlink:type="simple">10.1128/AAC.46.12.3984-3986.2002</ext-link></comment> <object-id pub-id-type="pmid">12435706</object-id>; PubMed Central PMCID: PMCPMC132751.</mixed-citation></ref>
<ref id="pone.0183510.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kluytmans-van den Bergh</surname> <given-names>MF</given-names></name>, <name name-style="western"><surname>Rossen</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Bruijning-Verhagen</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Bonten</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Friedrich</surname> <given-names>AW</given-names></name>, <name name-style="western"><surname>Vandenbroucke-Grauls</surname> <given-names>CM</given-names></name>, <etal>et al</etal>. <article-title>Whole-genome multilocus sequence typing of extended-spectrum-beta-lactamase-producing enterobacteriaceae</article-title>. <source>J Clin Microbiol</source>. <year>2016</year>;<volume>54</volume>(<issue>12</issue>):<fpage>2919</fpage>–<lpage>27</lpage>. Epub 2016/09/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JCM.01648-16" xlink:type="simple">10.1128/JCM.01648-16</ext-link></comment> <object-id pub-id-type="pmid">27629900</object-id>; PubMed Central PMCID: PMCPMC5121380.</mixed-citation></ref>
<ref id="pone.0183510.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garcia-Fernandez</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Morosini</surname> <given-names>MI</given-names></name>, <name name-style="western"><surname>Cobo</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Foruny</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Lopez-Sanroman</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Cobo</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Gut eradication of VIM-1 producing ST9 <italic>Klebsiella oxytoca</italic> after fecal microbiota transplantation for diarrhea caused by a <italic>Clostridium difficile</italic> hypervirulent R027 strain</article-title>. <source>Diagnostic microbiology and infectious disease</source>. <year>2016</year>;<volume>86</volume>(<issue>4</issue>):<fpage>470</fpage>–<lpage>1</lpage>. Epub 2016/11/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.diagmicrobio.2016.09.004" xlink:type="simple">10.1016/j.diagmicrobio.2016.09.004</ext-link></comment> <object-id pub-id-type="pmid">27712927</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shimada</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Kayama</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Shigemoto</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Hisatsune</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kuwahara</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Nishio</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Complete nucleotide sequence of pKOI-34, an IncL/M plasmid carrying blaIMP-34 in <italic>Klebsiella oxytoca</italic> isolated in Japan</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2016</year>;<volume>60</volume>(<issue>5</issue>):<fpage>3156</fpage>–<lpage>62</lpage>. Epub 2016/02/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.02507-15" xlink:type="simple">10.1128/AAC.02507-15</ext-link></comment> <object-id pub-id-type="pmid">26902770</object-id>; PubMed Central PMCID: PMCPMC4862478.</mixed-citation></ref>
<ref id="pone.0183510.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gallo</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Passaro</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Gasbarrini</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Landolfi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Montalto</surname> <given-names>M</given-names></name>. <article-title>Modulation of microbiota as treatment for intestinal inflammatory disorders: an uptodate</article-title>. <source>World journal of gastroenterology</source>. <year>2016</year>;<volume>22</volume>(<issue>32</issue>):<fpage>7186</fpage>–<lpage>202</lpage>. Epub 2016/09/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3748/wjg.v22.i32.7186" xlink:type="simple">10.3748/wjg.v22.i32.7186</ext-link></comment> <object-id pub-id-type="pmid">27621567</object-id>; PubMed Central PMCID: PMCPMC4997632.</mixed-citation></ref>
<ref id="pone.0183510.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Evans</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Salewski</surname> <given-names>RP</given-names></name>, <name name-style="western"><surname>Christman</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Girard</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Tompkins</surname> <given-names>TA</given-names></name>. <article-title>Effectiveness of <italic>Lactobacillus helveticus</italic> and <italic>Lactobacillus rhamnosus</italic> for the management of antibiotic-associated diarrhoea in healthy adults: a randomised, double-blind, placebo-controlled trial</article-title>. <source>The British journal of nutrition</source>. <year>2016</year>;<volume>116</volume>(<issue>1</issue>):<fpage>94</fpage>–<lpage>103</lpage>. Epub 2016/05/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1017/S0007114516001665" xlink:type="simple">10.1017/S0007114516001665</ext-link></comment> <object-id pub-id-type="pmid">27169634</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Didari</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Solki</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mozaffari</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nikfar</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Abdollahi</surname> <given-names>M</given-names></name>. <article-title>A systematic review of the safety of probiotics</article-title>. <source>Expert Opin Drug Saf</source>. <year>2014</year>;<volume>13</volume>(<issue>2</issue>):<fpage>227</fpage>–<lpage>39</lpage>. Epub 2014/01/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1517/14740338.2014.872627" xlink:type="simple">10.1517/14740338.2014.872627</ext-link></comment> <object-id pub-id-type="pmid">24405164</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref018"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Grand View Research. Probiotics market analysis by application (probiotic foods &amp; beverages (dairy products, non-dairy products, cereals, baked food, fermented meat products, dry food), probiotic dietary supplements (food supplements, nutritional supplements, specialty nutrients, infant formula), animal feed probiotics), by end-use (human probiotics, animal probiotics) and segment forecast to 2024. Research Reports in Nutraceuticals and Functional Foods: 2016 978-1-68038-093-4.</mixed-citation></ref>
<ref id="pone.0183510.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sulakvelidze</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Alavidze</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Morris</surname> <given-names>JG</given-names> <suffix>Jnr.</suffix></name> <article-title>Bacteriophage therapy</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2001</year>;<volume>45</volume>(<issue>3</issue>):<fpage>649</fpage>–<lpage>59</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.45.3.649-659.2001" xlink:type="simple">10.1128/AAC.45.3.649-659.2001</ext-link></comment> <object-id pub-id-type="pmid">11181338</object-id></mixed-citation></ref>
<ref id="pone.0183510.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chan</surname> <given-names>BK</given-names></name>, <name name-style="western"><surname>Abedon</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Loc-Carrillo</surname> <given-names>C</given-names></name>. <article-title>Phage cocktails and the future of phage therapy</article-title>. <source>Future Microbiol</source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<fpage>769</fpage>–<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2217/fmb.13.47" xlink:type="simple">10.2217/fmb.13.47</ext-link></comment> <object-id pub-id-type="pmid">23701332</object-id></mixed-citation></ref>
<ref id="pone.0183510.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Loc-Carrillo</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Abedon</surname> <given-names>ST</given-names></name>. <article-title>Pros and cons of phage therapy</article-title>. <source>Bacteriophage</source>. <year>2011</year>;<volume>1</volume>(<issue>2</issue>):<fpage>111</fpage>–<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4161/bact.1.2.14590" xlink:type="simple">10.4161/bact.1.2.14590</ext-link></comment> <object-id pub-id-type="pmid">22334867</object-id></mixed-citation></ref>
<ref id="pone.0183510.ref022"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">NIH. NIAID's Antibacterial Resistance Program: Current Status and Future Directions 2014 [March 26th 2016]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.niaid.nih.gov/topics/antimicrobialresistance/documents/arstrategicplan2014.pdf" xlink:type="simple">http://www.niaid.nih.gov/topics/antimicrobialresistance/documents/arstrategicplan2014.pdf</ext-link>.</mixed-citation></ref>
<ref id="pone.0183510.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abedon</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Kuhl</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Blasdel</surname> <given-names>BG</given-names></name>, <name name-style="western"><surname>Kutter</surname> <given-names>EM</given-names></name>. <article-title>Phage treatment of human infections</article-title>. <source>Bacteriophage</source>. <year>2011</year>;<volume>1</volume>(<issue>2</issue>):<fpage>66</fpage>–<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4161/bact.1.2.15845" xlink:type="simple">10.4161/bact.1.2.15845</ext-link></comment> <object-id pub-id-type="pmid">22334863</object-id></mixed-citation></ref>
<ref id="pone.0183510.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clark</surname> <given-names>JR</given-names></name>. <article-title>Bacteriophage therapy: history and future prospects</article-title>. <source>Future Virol</source>. <year>2015</year>;<volume>10</volume>(<issue>4</issue>):<fpage>449</fpage>–<lpage>61</lpage>.</mixed-citation></ref>
<ref id="pone.0183510.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kutter</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>De Vos</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Gvasalia</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Alavidze</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Gogokhia</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Kuhl</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Phage therapy in clinical practice: treatment of human infections</article-title>. <source>Curr Pharm Biotechnol</source>. <year>2010</year>;<volume>11</volume>(<issue>1</issue>):<fpage>69</fpage>–<lpage>86</lpage>. <object-id pub-id-type="pmid">20214609</object-id></mixed-citation></ref>
<ref id="pone.0183510.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brown</surname> <given-names>TL</given-names></name>, <name name-style="western"><surname>Petrovski</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Dyson</surname> <given-names>ZA</given-names></name>, <name name-style="western"><surname>Seviour</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Tucci</surname> <given-names>J</given-names></name>. <article-title>The formulation of bacteriophage in a semi solid preparation for control of <italic>Propionibacterium acnes</italic> growth</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>3</issue>):<fpage>e0151184</fpage>. Epub 2016/03/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0151184" xlink:type="simple">10.1371/journal.pone.0151184</ext-link></comment> <object-id pub-id-type="pmid">26964063</object-id>; PubMed Central PMCID: PMCPMC4786141.</mixed-citation></ref>
<ref id="pone.0183510.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>L-K</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>Y-L</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>K-C</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>N-T</given-names></name>, <name name-style="western"><surname>Lai</surname> <given-names>M-J</given-names></name>, <etal>et al</etal>. <article-title>Potential of bacteriophage ΦAB2 as an environmental biocontrol agent for the control of multidrug-resistant <italic>Acinetobacter baumannii</italic></article-title>. <source>BMC Microbiol</source>. <year>2013</year>;<volume>13</volume>(<issue>1</issue>):<fpage>154</fpage>.</mixed-citation></ref>
<ref id="pone.0183510.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>O'Flaherty</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ross</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Meaney</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Fitzgerald</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Elbreki</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Coffey</surname> <given-names>A</given-names></name>. <article-title>Potential of the polyvalent anti-<italic>Staphylococcus</italic> Bacteriophage K for control of antibiotic-resistant <italic>Staphylococci</italic> from hospitals</article-title>. <source>Appl and Environ Microbiol</source>. <year>2005</year>;<volume>71</volume>(<issue>4</issue>):<fpage>1836</fpage>–<lpage>42</lpage>.</mixed-citation></ref>
<ref id="pone.0183510.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brown</surname> <given-names>TL</given-names></name>, <name name-style="western"><surname>Thomas</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Odgers</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Petrovski</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Spark</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Tucci</surname> <given-names>J</given-names></name>. <article-title>Bacteriophage formulated into a range of semisolid and solid dosage forms maintain lytic capacity against isolated cutaneous and opportunistic oral bacteria</article-title>. <source>J Pharm Pharmacol</source>. <year>2016</year>. Epub 2016/12/30. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/jphp.12673" xlink:type="simple">10.1111/jphp.12673</ext-link></comment> <object-id pub-id-type="pmid">28033675</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kęsik-Szeloch</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Drulis-Kawa</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Weber-Dąbrowska</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Kassner</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Majkowska-Skrobek</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Augustyniak</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Characterising the biology of novel lytic bacteriophages infecting multidrug resistant <italic>Klebsiella pneumoniae</italic></article-title>. <source>Virol J</source>. <year>2013</year>;<volume>10</volume>(<issue>1</issue>):<fpage>100</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1743-422x-10-100" xlink:type="simple">10.1186/1743-422x-10-100</ext-link></comment> <object-id pub-id-type="pmid">23537199</object-id></mixed-citation></ref>
<ref id="pone.0183510.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karumidze</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Kusradze</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Rigvava</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Goderdzishvili</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Rajakumar</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Alavidze</surname> <given-names>Z</given-names></name>. <article-title>Isolation and characterisation of lytic bacteriophages of <italic>Klebsiella pneumoniae</italic> and <italic>Klebsiella oxytoca</italic></article-title>. <source>Current Microbiol</source>. <year>2013</year>;<volume>66</volume>(<issue>3</issue>):<fpage>251</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00284-012-0264-7" xlink:type="simple">10.1007/s00284-012-0264-7</ext-link></comment> <object-id pub-id-type="pmid">23143289</object-id></mixed-citation></ref>
<ref id="pone.0183510.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Turner</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pryer</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Miao</surname> <given-names>VP</given-names></name>, <name name-style="western"><surname>Palmer</surname> <given-names>JD</given-names></name>. <article-title>Investigating deep phylogenetic relationships among cyanobacteria and plastids by small subunit rRNA sequence analysis</article-title>. <source>The Journal of eukaryotic microbiology</source>. <year>1999</year>;<volume>46</volume>(<issue>4</issue>):<fpage>327</fpage>–<lpage>38</lpage>. Epub 1999/08/26. <object-id pub-id-type="pmid">10461381</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hodkinson</surname> <given-names>BP</given-names></name>, <name name-style="western"><surname>Lutzoni</surname> <given-names>F</given-names></name>. <article-title>A microbiotic survey of lichen-associated bacteria reveals a new lineage from the Rhizobiales</article-title>. <source>Symbiosis</source>. <year>2009</year>;<volume>49</volume>(<issue>3</issue>):<fpage>163</fpage>–<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s13199-009-0049-3" xlink:type="simple">10.1007/s13199-009-0049-3</ext-link></comment></mixed-citation></ref>
<ref id="pone.0183510.ref034"><label>34</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Lane</surname> <given-names>DJ</given-names></name>. <chapter-title>16S/23S rRNA sequencing</chapter-title>. In: <name name-style="western"><surname>Stackebrandt</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Goodfellow</surname> <given-names>M</given-names></name>, editors. <source>Nucleic acid techniques in bacterial systematics</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>John Wiley and Sons</publisher-name>; <year>1991</year>. p. <fpage>115</fpage>–<lpage>75</lpage>.</mixed-citation></ref>
<ref id="pone.0183510.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kovtunovych</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Lytvynenko</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Negrutska</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Lar</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Brisse</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kozyrovska</surname> <given-names>N</given-names></name>. <article-title>Identification of <italic>Klebsiella oxytoca</italic> using a specific PCR assay targeting the polygalacturonase pehX gene</article-title>. <source>Res Microbiol</source>. <year>2003</year>;<volume>154</volume>(<issue>8</issue>):<fpage>587</fpage>–<lpage>92</lpage>. Epub 2003/10/07. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0923-2508(03)00148-7" xlink:type="simple">10.1016/S0923-2508(03)00148-7</ext-link></comment> <object-id pub-id-type="pmid">14527660</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Petrovski</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Seviour</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Tillett</surname> <given-names>D</given-names></name>. <article-title>Genome sequence and characterization of the <italic>Tsukamurella</italic> bacteriophage TPA2</article-title>. <source>App Environ Microbiol</source>. <year>2011</year>;<volume>77</volume>(<issue>4</issue>):<fpage>1389</fpage>–<lpage>98</lpage>.</mixed-citation></ref>
<ref id="pone.0183510.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Laslett</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Canback</surname> <given-names>B</given-names></name>. <article-title>ARAGORN, a program to detect tRNA genes and tmRNA genes in nucleotide sequences</article-title>. <source>Nucleic Acids Res</source>. <year>2004</year>;<volume>32</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gkh152" xlink:type="simple">10.1093/nar/gkh152</ext-link></comment> <object-id pub-id-type="pmid">14704338</object-id></mixed-citation></ref>
<ref id="pone.0183510.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schattner</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Brooks</surname> <given-names>AN</given-names></name>, <name name-style="western"><surname>Lowe</surname> <given-names>TM</given-names></name>. <article-title>The tRNAscan-SE, snoscan and snoGPS web servers for the detection of tRNAs and snoRNAs</article-title>. <source>Nucleic Acids Res</source>. <year>2005</year>;<volume>33</volume>(<issue>suppl 2</issue>):<fpage>W686</fpage>–<lpage>W9</lpage>.</mixed-citation></ref>
<ref id="pone.0183510.ref039"><label>39</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Adams</surname> <given-names>MH</given-names></name>. <source>Bacteriophages</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Interscience Publishers</publisher-name>; <year>1959</year>.</mixed-citation></ref>
<ref id="pone.0183510.ref040"><label>40</label><mixed-citation publication-type="book" xlink:type="simple"><collab>United States Pharmacopeial Convention</collab>. <source>U.S. Pharmacopeia National Formulary 2017: USP 40 NF 35</source>. <publisher-loc>USA</publisher-loc>: <publisher-name>United States Pharmacopeial</publisher-name>; <year>2016</year>.</mixed-citation></ref>
<ref id="pone.0183510.ref041"><label>41</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Sansom</surname> <given-names>L</given-names></name>, editor. <source>Australian Pharmaceutical Formulary and Handbook</source>. <edition>23rd ed.</edition> <publisher-loc>Canberra</publisher-loc>: <publisher-name>Pharmaceutical Society of Australia</publisher-name>; <year>2015</year>.</mixed-citation></ref>
<ref id="pone.0183510.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stojowska-Swedrzynska</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Krawczyk</surname> <given-names>B</given-names></name>. <article-title>A new assay for the simultaneous identification and differentiation of <italic>Klebsiella oxytoca</italic> strains</article-title>. <source>Appl Microbiol Biotechnol</source>. <year>2016</year>. Epub 2016/10/09. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00253-016-7881-1" xlink:type="simple">10.1007/s00253-016-7881-1</ext-link></comment> <object-id pub-id-type="pmid">27717967</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Park</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YT</given-names></name>, <name name-style="western"><surname>Cho</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Ryu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JH</given-names></name>. <article-title>Characterization and genome analysis of novel bacteriophages infecting the opportunistic human pathogens <italic>Klebsiella oxytoca</italic> and <italic>K</italic>. <italic>pneumoniae</italic></article-title>. <source>Arch Virol</source>. <year>2016</year>. Epub 2016/12/29. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00705-016-3202-3" xlink:type="simple">10.1007/s00705-016-3202-3</ext-link></comment> <object-id pub-id-type="pmid">28028618</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marraffini</surname> <given-names>LA</given-names></name>. <article-title>CRISPR-Cas immunity in prokaryotes</article-title>. <source>Nature</source>. <year>2015</year>;<volume>526</volume>(<issue>7571</issue>):<fpage>55</fpage>–<lpage>61</lpage>. Epub 2015/10/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature15386" xlink:type="simple">10.1038/nature15386</ext-link></comment> <object-id pub-id-type="pmid">26432244</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ostria-Hernández</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Sánchez-Vallejo</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Ibarra</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Castro-Escarpulli</surname> <given-names>G</given-names></name>. <article-title>Survey of clustered regularly interspaced short palindromic repeats and their associated Cas proteins (CRISPR/Cas) systems in multiple sequenced strains of <italic>Klebsiella pneumoniae</italic></article-title>. <source>BMC Res Notes</source>. <year>2015</year>;<volume>8</volume>(<issue>1</issue>):<fpage>332</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13104-015-1285-7" xlink:type="simple">10.1186/s13104-015-1285-7</ext-link></comment> <object-id pub-id-type="pmid">26238567</object-id></mixed-citation></ref>
<ref id="pone.0183510.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Netzer</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Gaia</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Sandoz</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Huluk</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Gut</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Halter</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours</article-title>. <source>The American journal of gastroenterology</source>. <year>1999</year>;<volume>94</volume>(<issue>2</issue>):<fpage>351</fpage>–<lpage>7</lpage>. Epub 1999/02/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1572-0241.1999.857_y.x" xlink:type="simple">10.1111/j.1572-0241.1999.857_y.x</ext-link></comment> <object-id pub-id-type="pmid">10022628</object-id>.</mixed-citation></ref>
<ref id="pone.0183510.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ma</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Pacan</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Korenevsky</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Microencapsulation of bacteriophage felix O1 into chitosan-alginate microspheres for oral delivery</article-title>. <source>Appl Environ Microbiol</source>. <year>2008</year>;<volume>74</volume>(<issue>15</issue>):<fpage>4799</fpage>–<lpage>805</lpage>. Epub 2008/06/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AEM.00246-08" xlink:type="simple">10.1128/AEM.00246-08</ext-link></comment> <object-id pub-id-type="pmid">18515488</object-id>; PubMed Central PMCID: PMCPMC2519356.</mixed-citation></ref>
</ref-list>
</back>
</article>